PENTOXIFYLLINE - Generic Drug Details

What are the generic sources for pentoxifylline and what is the scope of patent protection?

Pentoxifylline is the generic ingredient in three branded drugs marketed by Ani Pharms, Apotex, Bausch, Heritage, Impax Labs, Pliva, Rising, Upsher Smith Labs, and Validus Pharms, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for pentoxifylline. Seven suppliers are listed for this compound.

Summary for PENTOXIFYLLINE

US Patents:	0
Tradenames:	3
Applicants:	9
NDAs:	11
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	184
Drug Prices:	Drug price trends for PENTOXIFYLLINE
What excipients (inactive ingredients) are in PENTOXIFYLLINE?	PENTOXIFYLLINE excipients list
DailyMed Link:	PENTOXIFYLLINE at DailyMed

See drug prices for PENTOXIFYLLINE

Recent Clinical Trials for PENTOXIFYLLINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ihab Elsayed Hassan	PHASE2
William Stoops	EARLY_PHASE1
National Institute on Drug Abuse (NIDA)	EARLY_PHASE1

See all PENTOXIFYLLINE clinical trials

Pharmacology for PENTOXIFYLLINE

Drug Class	Blood Viscosity Reducer
Physiological Effect	Hematologic Activity Alteration

Medical Subject Heading (MeSH) Categories for PENTOXIFYLLINE

Free Radical Scavengers

Phosphodiesterase Inhibitors

Platelet Aggregation Inhibitors

Radiation-Protective Agents

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for PENTOXIFYLLINE

C04AD	Purine derivatives
C04A	PERIPHERAL VASODILATORS
C04	PERIPHERAL VASODILATORS
C	Cardiovascular system

US Patents and Regulatory Information for PENTOXIFYLLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pliva	PENTOXIFYLLINE	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074874-001	May 25, 1999		DISCN	No	No
Ani Pharms	PENTOXIFYLLINE	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074878-001	Jul 9, 1997	AB	RX	No	No
Rising	PENTOXIFYLLINE	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074425-001	Jul 8, 1997	AB	RX	No	No
Upsher Smith Labs	PENTOXIL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074962-001	Mar 31, 1999		DISCN	No	No

Expired US Patents for PENTOXIFYLLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984

Market Dynamics and Financial Trajectory of Pentoxifylline

Last updated: February 20, 2026

Pentoxifylline (PTX) is a methylxanthine derivative primarily used to improve blood flow in peripheral vascular disease. Although initially marketed as a treatment for intermittent claudication, the drug's broader applications and market potential are evolving.

Market Overview

The global pentoxifylline market was valued at approximately USD 100 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030. Growth drivers include increased off-label use, expanded indications, and rising prevalence of peripheral vascular diseases.

Key Indications and Off-Label Uses

• Vascular disorders: Intermittent claudication, peripheral arterial disease
• Cerebral ischemia: Off-label for stroke recovery
• Liver conditions: Hepatic encephalopathy adjunct
• Other: Claimed benefits in psoriasis and certain wound healing indications

Regulatory authorization varies by country. The US Food and Drug Administration (FDA) approved PTX for "intermittent claudication" but has not licensed it for other off-label uses. In contrast, several European nations prescribe PTX in broader contexts.

Market Participants and Distribution

Major pharmaceutical firms operating in this space include:

• Mylan (now part of Viatris): Historically a leading supplier
• Fresenius: Offers PTX formulations in select markets
• Generics manufacturers: Contribute significantly to market volume due to the drug's patent expiration

Patent expiration occurred in the early 2000s, leading to a proliferation of generic versions that dominate sales volumes.

Pricing Trends and Revenue Streams

Generic versions of pentoxifylline sell at annual prices typically ranging from USD 20 to 50 per patient, depending on the formulation and market. Market leaders have seen revenues decline in recent years due to generic competition.

Average annual revenues for pentoxifylline are around USD 80-100 million globally. Revenue is concentrated in Europe and parts of Asia, with less in North America owing to regulatory and prescribing preferences.

Regulatory and Patent Landscape

The original patent on pentoxifylline expired approximately 20 years ago, enabling widespread generics. Current patents focus on novel formulations or delivery mechanisms, which do not significantly impact the primary market.

Market Challenges

• Off-label use: Regulatory restrictions limit growth
• Efficacy debates: Variability in clinical trial outcomes influences physician prescribing
• Emerging therapies: Newer drugs for vascular and neurological conditions threaten market share

Financial Trajectory and Future Outlook

Projected growth hinges on several factors:

• Expanding indications: Evidence supporting new uses could boost market size
• Regulatory approval in emerging markets: China and India show increased prescribing, potentially raising revenues
• Manufacturing efficiencies: Cost reductions via generics could sustain profitability

However, growth faces barriers from:

• Competition from better-evidenced therapies
• Regulatory restrictions limiting off-label use

Analysts forecast modest CAGR of 2-4% over the next decade, driven predominantly by generics sales and regional market expansion.

Strategic Recommendations

• Monitor regulatory developments, especially in emerging markets
• Invest in research to establish efficacy for new indications
• Explore formulation innovations to differentiate products

Key Takeaways

1. The global pentoxifylline market was valued at USD 100 million in 2022, with growth prospects modest at 4-6% CAGR through 2030.
2. Generics dominate the market due to patent expiry, leading to pricing pressures.
3. Revenue concentrated in Europe and Asia, with declining North American market share.
4. Market growth is constrained by regulatory restrictions, efficacy debates, and competition from newer therapies.
5. Future expansion may result from novel formulations, new indications, and regional market penetration.

FAQs

1. Can pentoxifylline be prescribed off-label in the US?
Yes, but such use is not FDA-approved and depends on physician discretion and regional regulations.

2. What factors are limiting pentoxifylline's market growth?
Regulatory restrictions, questioning of clinical efficacy, competition from emerging drugs, and limited approval for expanded indications.

3. How does patent expiration affect pentoxifylline's market?
Patent expiry enables generic manufacturers to produce lower-priced versions, leading to revenue declines for original branded products.

4. Are there ongoing research efforts for new therapeutic applications of pentoxifylline?
Some studies are exploring its potential benefits in hepatic conditions and neurological recovery, but results are inconclusive.

5. What regional markets are seeing the fastest adoption of pentoxifylline?
Emerging markets such as China and India exhibit increased prescribing, driven by cost advantages and established generic distribution.

References

1. MarketWatch. (2023). Pentoxifylline Market Value & Forecast. https://www.marketwatch.com
2. U.S. Food and Drug Administration. Drug Approval Records. https://www.fda.gov
3. Global Data. (2022). Pharmaceutical Market Reports. https://www.globaldata.com